4.5 Review

Clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound regression/progression studies

期刊

EUROINTERVENTION
卷 6, 期 9, 页码 1123-1130

出版社

EUROPA EDITION
DOI: 10.4244/EIJV6I9A195

关键词

-

资金

  1. GlaxoSmithKlein
  2. Astra Zeneca
  3. Boston Scientific
  4. Merck
  5. Illy Lilly
  6. Volcano

向作者/读者索取更多资源

Atherosclerotic cardiovascular disease is a leading cause of morbidity and mortality despite the widespread use of established medical therapies. This has prompted the search to identify new therapeutic approaches to achieve more effective prevention of cardiovascular events. Considerable interest has focused on the role of surrogate markers of therapeutic efficacy in the early evaluation of novel anti-atherosclerotic therapies. Monitoring changes in the extent of coronary atherosclerosis with intravascular ultrasound (IVUS) has been increasingly employed in clinical trials to assess progression and regression of atherosclerosis. This is based on the pivotal role that atherosclerotic plaque plays in the natural history of cardiovascular disease and the acceptance of validated arterial imaging approaches including coronary angiography and carotid intimal-medial thickness by regulatory authorities. The ability to generate high-resolution imaging of the entire thickness of the coronary artery wall permits evaluation of the entire burden of atherosclerotic plaque. In order to understand the differences, similarities, limitations and pitfalls of the IVUS technique among different academic core laboratories, a number of meetings of representatives from these groups were convened in 2007 and 2008. This document is result of those IVUS methodology meetings that assembled experts from core laboratories to discuss standards for image acquisition, definitions, criteria, analyses, and primary and secondary endpoints.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据